Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.13
26.31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc., a biopharmaceutical company founded with a determined focus on developing innovative therapies, has systematically carved out a niche in the treatment of rare neuromuscular and neurological diseases. Headquartered in Coral Gables, Florida, the company emerged as a lifeline for patients grappling with these debilitating conditions, particularly targeting those with limited treatment options. At the heart of Catalyst’s business model is its flagship product, Firdapse (amifampridine), a pioneering medication approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). This niche focus allows Catalyst to not only address unmet medical needs but also to navigate a less crowded competitive landscape, where larger pharmaceutical giants often overlook rare conditions.
Catalyst Pharmaceuticals' revenue stream is primarily derived from the commercial sales of Firdapse, which has gained traction in the rare disease market due to its status as a first-line treatment. The company adopts a strategic approach by exclusively concentrating on rare diseases, benefiting from incentives such as orphan drug designations, which often include extended market exclusivity, tax credits, and potential grants. This strategy is bolstered by an experienced management team that adeptly leverages Catalyst’s research capabilities and regulatory know-how, ensuring a robust pipeline poised for future growth. By maintaining strong relationships with healthcare providers and patient advocacy groups, Catalyst Pharmaceuticals reinforces its commitment to patient-centric solutions, enabling both sustained market presence and organic growth within its specialized field.
Catalyst Pharmaceuticals Inc., a biopharmaceutical company founded with a determined focus on developing innovative therapies, has systematically carved out a niche in the treatment of rare neuromuscular and neurological diseases. Headquartered in Coral Gables, Florida, the company emerged as a lifeline for patients grappling with these debilitating conditions, particularly targeting those with limited treatment options. At the heart of Catalyst’s business model is its flagship product, Firdapse (amifampridine), a pioneering medication approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). This niche focus allows Catalyst to not only address unmet medical needs but also to navigate a less crowded competitive landscape, where larger pharmaceutical giants often overlook rare conditions.
Catalyst Pharmaceuticals' revenue stream is primarily derived from the commercial sales of Firdapse, which has gained traction in the rare disease market due to its status as a first-line treatment. The company adopts a strategic approach by exclusively concentrating on rare diseases, benefiting from incentives such as orphan drug designations, which often include extended market exclusivity, tax credits, and potential grants. This strategy is bolstered by an experienced management team that adeptly leverages Catalyst’s research capabilities and regulatory know-how, ensuring a robust pipeline poised for future growth. By maintaining strong relationships with healthcare providers and patient advocacy groups, Catalyst Pharmaceuticals reinforces its commitment to patient-centric solutions, enabling both sustained market presence and organic growth within its specialized field.
Record Revenue: Catalyst reported Q3 2025 revenue of $148.4 million, up 15.3% year-over-year, driven by strong performance across FIRDAPSE, AGAMREE, and FYCOMPA.
Upside Guidance: Full-year 2025 total revenue guidance was raised to $565–585 million, reflecting confidence in continued growth.
FIRDAPSE Momentum: FIRDAPSE posted $92.2 million in Q3 revenue, up 16.2% year-over-year; full-year guidance for FIRDAPSE was reaffirmed at $355–360 million.
AGAMREE Outperformance: AGAMREE revenue soared 115.2% to $32.4 million in Q3; full-year guidance for AGAMREE raised to $105–115 million.
FYCOMPA Resilience: FYCOMPA delivered $23.8 million in Q3 revenue, despite generic entry; full-year guidance increased to $100–110 million, though management expects further erosion as more generics enter.
Cash & Buyback: The company ended Q3 with $689.9 million in cash and no debt, and announced a new $200 million share repurchase program.
Commercial Execution: Management highlighted strong patient retention, broadening payer support, and commercial expansion, particularly for rare disease therapies.
IP & Legal: Patent litigation for FIRDAPSE is ongoing with one case remaining; management remains confident in IP strength.
